BofA analyst Michael Ryskin has adjusted the price target for Charles River Laboratories (CRL, Financial), reducing it from $185 to $150, while maintaining a Neutral rating on the stock. This adjustment comes in light of growing negative sentiment surrounding the Life Sciences and Diagnostic Tools sectors, and Contract Research Organizations as they approach earnings announcements.
The sector is facing several policy-driven challenges, including lingering effects from the Trump Administration's policies. These include funding cuts to the National Institutes of Health (NIH) and the impact of global tariffs. Broader economic concerns, particularly those related to China, are also contributing to the cautious outlook for these companies.
Ryskin's analysis highlights the pressure points at the intersection of these policy changes and macroeconomic factors, which have been shaping the current sentiment in the industry. Investors are advised to keep these developments in mind as companies in this sector prepare to release their earnings.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 15 analysts, the average target price for Charles River Laboratories International Inc (CRL, Financial) is $158.40 with a high estimate of $215.00 and a low estimate of $70.00. The average target implies an upside of 53.13% from the current price of $103.44. More detailed estimate data can be found on the Charles River Laboratories International Inc (CRL) Forecast page.
Based on the consensus recommendation from 20 brokerage firms, Charles River Laboratories International Inc's (CRL, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Charles River Laboratories International Inc (CRL, Financial) in one year is $203.78, suggesting a upside of 97% from the current price of $103.44. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Charles River Laboratories International Inc (CRL) Summary page.
